Logo image of AXGN

AXOGEN INC (AXGN) Stock Fundamental Analysis

USA - NASDAQ:AXGN - US05463X1063 - Common Stock

17.6 USD
+0.4 (+2.33%)
Last: 9/22/2025, 9:27:00 PM
17.59 USD
-0.01 (-0.06%)
After Hours: 9/22/2025, 9:27:00 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to AXGN. AXGN was compared to 190 industry peers in the Health Care Equipment & Supplies industry. AXGN has only an average score on both its financial health and profitability. AXGN has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

AXGN had positive earnings in the past year.
In the past year AXGN had a positive cash flow from operations.
AXGN had negative earnings in each of the past 5 years.
In the past 5 years AXGN reported 4 times negative operating cash flow.
AXGN Yearly Net Income VS EBIT VS OCF VS FCFAXGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

AXGN has a better Return On Assets (-2.27%) than 67.37% of its industry peers.
AXGN has a better Return On Equity (-4.15%) than 69.47% of its industry peers.
AXGN has a better Return On Invested Capital (0.75%) than 66.32% of its industry peers.
Industry RankSector Rank
ROA -2.27%
ROE -4.15%
ROIC 0.75%
ROA(3y)-10.24%
ROA(5y)-11.1%
ROE(3y)-20.3%
ROE(5y)-20.84%
ROIC(3y)N/A
ROIC(5y)N/A
AXGN Yearly ROA, ROE, ROICAXGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

AXGN's Operating Margin of 0.84% is fine compared to the rest of the industry. AXGN outperforms 65.26% of its industry peers.
AXGN has a better Gross Margin (74.27%) than 85.79% of its industry peers.
AXGN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 0.84%
PM (TTM) N/A
GM 74.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-1.5%
AXGN Yearly Profit, Operating, Gross MarginsAXGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

6

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AXGN is destroying value.
AXGN has more shares outstanding than it did 1 year ago.
AXGN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AXGN has an improved debt to assets ratio.
AXGN Yearly Shares OutstandingAXGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AXGN Yearly Total Debt VS Total AssetsAXGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 4.56 indicates that AXGN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.56, AXGN is in the better half of the industry, outperforming 77.37% of the companies in the same industry.
AXGN has a debt to FCF ratio of 13.85. This is a negative value and a sign of low solvency as AXGN would need 13.85 years to pay back of all of its debts.
AXGN has a Debt to FCF ratio of 13.85. This is in the better half of the industry: AXGN outperforms 72.11% of its industry peers.
AXGN has a Debt/Equity ratio of 0.43. This is a healthy value indicating a solid balance between debt and equity.
AXGN's Debt to Equity ratio of 0.43 is in line compared to the rest of the industry. AXGN outperforms 43.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF 13.85
Altman-Z 4.56
ROIC/WACC0.08
WACC8.97%
AXGN Yearly LT Debt VS Equity VS FCFAXGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

AXGN has a Current Ratio of 4.14. This indicates that AXGN is financially healthy and has no problem in meeting its short term obligations.
AXGN's Current ratio of 4.14 is fine compared to the rest of the industry. AXGN outperforms 70.53% of its industry peers.
A Quick Ratio of 2.67 indicates that AXGN has no problem at all paying its short term obligations.
AXGN has a Quick ratio of 2.67. This is in the better half of the industry: AXGN outperforms 64.21% of its industry peers.
Industry RankSector Rank
Current Ratio 4.14
Quick Ratio 2.67
AXGN Yearly Current Assets VS Current LiabilitesAXGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 500.00% over the past year.
AXGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.17%.
The Revenue has been growing by 11.92% on average over the past years. This is quite good.
EPS 1Y (TTM)500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
Revenue 1Y (TTM)17.17%
Revenue growth 3Y13.72%
Revenue growth 5Y11.92%
Sales Q2Q%18.26%

3.2 Future

Based on estimates for the next years, AXGN will show a very strong growth in Earnings Per Share. The EPS will grow by 50.38% on average per year.
The Revenue is expected to grow by 16.23% on average over the next years. This is quite good.
EPS Next Y100.08%
EPS Next 2Y92.71%
EPS Next 3Y90.78%
EPS Next 5Y50.38%
Revenue Next Year17.84%
Revenue Next 2Y16.84%
Revenue Next 3Y15.02%
Revenue Next 5Y16.23%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AXGN Yearly Revenue VS EstimatesAXGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
AXGN Yearly EPS VS EstimatesAXGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5

5

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 73.33, the valuation of AXGN can be described as expensive.
Based on the Price/Earnings ratio, AXGN is valued a bit cheaper than the industry average as 66.32% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.41. AXGN is valued rather expensively when compared to this.
AXGN is valuated quite expensively with a Price/Forward Earnings ratio of 36.45.
Based on the Price/Forward Earnings ratio, AXGN is valued a bit cheaper than the industry average as 71.58% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of AXGN to the average of the S&P500 Index (22.87), we can say AXGN is valued expensively.
Industry RankSector Rank
PE 73.33
Fwd PE 36.45
AXGN Price Earnings VS Forward Price EarningsAXGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

63.16% of the companies in the same industry are more expensive than AXGN, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, AXGN is valued a bit cheaper than the industry average as 67.89% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 233.7
EV/EBITDA 86.03
AXGN Per share dataAXGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

AXGN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AXGN's earnings are expected to grow with 90.78% in the coming years.
PEG (NY)0.73
PEG (5Y)N/A
EPS Next 2Y92.71%
EPS Next 3Y90.78%

0

5. Dividend

5.1 Amount

AXGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

AXOGEN INC

NASDAQ:AXGN (9/22/2025, 9:27:00 PM)

After market: 17.59 -0.01 (-0.06%)

17.6

+0.4 (+2.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners86.63%
Inst Owner Change1.79%
Ins Owners0.92%
Ins Owner Change-0.41%
Market Cap809.78M
Analysts84.29
Price Target25.37 (44.15%)
Short Float %5.86%
Short Ratio1.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-68.39%
Min EPS beat(2)-222.55%
Max EPS beat(2)85.77%
EPS beat(4)3
Avg EPS beat(4)275.79%
Min EPS beat(4)-222.55%
Max EPS beat(4)1125.49%
EPS beat(8)7
Avg EPS beat(8)185.94%
EPS beat(12)11
Avg EPS beat(12)146.94%
EPS beat(16)14
Avg EPS beat(16)116.93%
Revenue beat(2)1
Avg Revenue beat(2)2%
Min Revenue beat(2)-1.48%
Max Revenue beat(2)5.47%
Revenue beat(4)2
Avg Revenue beat(4)1.26%
Min Revenue beat(4)-1.48%
Max Revenue beat(4)5.47%
Revenue beat(8)5
Avg Revenue beat(8)1.38%
Revenue beat(12)7
Avg Revenue beat(12)0.53%
Revenue beat(16)7
Avg Revenue beat(16)-0.53%
PT rev (1m)2.58%
PT rev (3m)2.58%
EPS NQ rev (1m)2.39%
EPS NQ rev (3m)7.5%
EPS NY rev (1m)0%
EPS NY rev (3m)22.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.33%
Valuation
Industry RankSector Rank
PE 73.33
Fwd PE 36.45
P/S 3.98
P/FCF 233.7
P/OCF 112.67
P/B 7.21
P/tB 7.63
EV/EBITDA 86.03
EPS(TTM)0.24
EY1.36%
EPS(NY)0.48
Fwd EY2.74%
FCF(TTM)0.08
FCFY0.43%
OCF(TTM)0.16
OCFY0.89%
SpS4.42
BVpS2.44
TBVpS2.31
PEG (NY)0.73
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.27%
ROE -4.15%
ROCE 0.95%
ROIC 0.75%
ROICexc 0.9%
ROICexgc 0.94%
OM 0.84%
PM (TTM) N/A
GM 74.27%
FCFM 1.7%
ROA(3y)-10.24%
ROA(5y)-11.1%
ROE(3y)-20.3%
ROE(5y)-20.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-1.5%
F-Score6
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF 13.85
Debt/EBITDA 5.16
Cap/Depr 49.09%
Cap/Sales 1.83%
Interest Coverage 0.24
Cash Conversion 77.33%
Profit Quality N/A
Current Ratio 4.14
Quick Ratio 2.67
Altman-Z 4.56
F-Score6
WACC8.97%
ROIC/WACC0.08
Cap/Depr(3y)337.29%
Cap/Depr(5y)669.18%
Cap/Sales(3y)9.04%
Cap/Sales(5y)13.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
EPS Next Y100.08%
EPS Next 2Y92.71%
EPS Next 3Y90.78%
EPS Next 5Y50.38%
Revenue 1Y (TTM)17.17%
Revenue growth 3Y13.72%
Revenue growth 5Y11.92%
Sales Q2Q%18.26%
Revenue Next Year17.84%
Revenue Next 2Y16.84%
Revenue Next 3Y15.02%
Revenue Next 5Y16.23%
EBIT growth 1Y114.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1384.37%
EBIT Next 3Y205.47%
EBIT Next 5YN/A
FCF growth 1Y112.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y211.25%
OCF growth 3YN/A
OCF growth 5YN/A